EUVIMEDEUVIMED entdecken
CrossrefInfokarte

HPV Genotype Distribution in Cervical Cancer and High‐Grade Lesions in Norway, and Early Vaccine Impact

Terese Bekkevold, Ida Laake, Berit Feiring, Kristiane Søreng, Gro Kummeneje Presthus, Glenny Cecilie Alfsen, Irene Kraus Christiansen, Mona Hansen, Hanne Kristiansen, Eirik Olsen, Torstein Gjølgali Frengen, Emily A. Burger, Christine Genieve Monceyron Jonassen, Lill Trogstad

International Journal of Cancer · 2027-01-01 · 160 (1) · 171-186

DOI: 10.1002/ijc.70712 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT All cases of invasive cervical cancer (ICC) and subsets of high‐grade cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) and adenocarcinoma in situ (AIS) in Norway are tested for 37 human papillomavirus (HPV) genotypes, within a mandatory national surveillance system. We assessed the proportional attribution of HPV types in cervical lesions from predominantly unvaccinated women reported during 2017–2021 (baseline population) and the HPV type distribution by vaccination status in vaccine‐eligible cases reported during 2017–2024. Among baseline CIN2/3 cases ( n = 3087), 48% were attributable to HPV16/18, 28% to HPV31/33/45, 12% to HPV52/58 and 8% to other high‐risk types (HPV35/39/51/56/59). For AIS ( n = 550), almost all cases were attributed to HPV16/18 (91%) and HPV45 (6%). For ICC ( n = 1265), 75% were attributable to HPV16/18, 15% to HPV31/33/45, 3% to HPV52/58 and 4% to other high‐risk types. Among CIN2/3 cases born 1997 or later (eligible for vaccination at age 11–12 years, n = 154), HPV16‐attribution was higher in unvaccinated cases (49.9%, 95% CI: 33.7–66.1) than in cases vaccinated before age 15 (1.1%, 95% CI: 0–3.4). In CIN2/3 cases born 1991–1996 (eligible for catch‐up vaccination, n = 1541), HPV16‐attribution was 45.7% (95% CI: 41.9–49.7) in unvaccinated versus 35.5% (95% CI: 32.5–38.6) in vaccinated cases. Minor differences by vaccination status were observed for catch‐up‐eligible AIS ( n = 445) and ICC ( n = 135) cases. In conclusion, the baseline genotype distribution in high‐grade cervical lesions and ICC in Norway aligns with global data. Strong protection against HPV16‐induced CIN2/3 was seen in women vaccinated before age 15 years.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →